M. Flint Beal, M.D.

Neurology
M. Beal

M. Flint Beal, MD is an internationally recognized authority on neurodegenerative disorders. He is University Professor  at the Brain and ind Institute of Weill Cornell Medical College.   Dr. Beal received his medical degree from the University of Virginia in 1976 and did his internship and first year residency in Medicine at New York-Cornell before completing his residency in Neurology at The Massachusetts General Hospital. He joined the neurology faculty at Harvard in 1983. Dr. Beal was Professor of Neurology at the Harvard Medical School and Chief of the Neurochemistry laboratory at Massachusetts General Hospital before moving to Cornell. Dr. Beal's research has focused on the mechanism of neuronal degeneration in Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and amyotrophic lateral sclerosis (ALS).

Dr. Beal is the author or co-author of more than 500 scientific articles and more than 125 books, book chapters and reviews. He serves on the editorial boards of seven journals, the Journal of Neurochemistry, the Annals of Neurology, Journal of Molecular Neuroscience, Experimental Neurology and Neurobiology of Disease. Dr. Beal's research has focused on the mechanism of neuronal degeneration in Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and amyotrophic lateral sclerosis (ALS). He has also been working on the development of novel neurochemical assays for assessing oxidative damage for use in clinical trials of new therapies for these disorders, as well as metabolomics for diagnosis.

Dr. Beal is a member of the Alpha Omega Alpha Medical Honorary Society and received the Derek Denny-Brown Neurological Scholar Award of the American Neurological Association. He has served on the Council and as Vice President of the American Neurological Association and on the Science Advisory Committees of the Hereditary Disease Foundation, Huntington's Disease Society of America, Parkinson's Disease Study Group, Parkinson' Disease Foundation, Bachman-Strauss Foundation, The ALS Association, and the American Health Assistance Foundation. Dr. Beal is also a member of the Institute of Medicine of the Namtional Academy of Sciences.

Selected Recent Papers (downloadable in Adobe Acrobat format*):

Energetics in the pathogenesis of neurodegenerative diseases

Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795

Therapeutic effects of coenzyme Q10 and reduced COQ10 in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinsonism.  J Neurochem 2008; 104:1613-1621

Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131:389-96.

*If you don't have Acrobat Reader 3.0 or higher, you can download it from Adobe's website.

Publications

Recent Publications

Sugama S., Yang L, Cho BP, DeGiorgio L, Lorenzl S, Albers D, Beal MF. Age-related microglial activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003;964:288-294

Paul S, Bogdanov MB, Matson WR, Metakis L, Jacobs J, Beal MF. Urinary 8-hydroxy-2'-deoxyguanosine, a metabolite of oxidized DNA, is not elevated in HIV patients on combiantion antiretroviral therapy. Free Rad Res 2003, 37:499-502

Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, Beal MF. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003:85:142-150

Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg S, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase 9 in patients with Alzheimer's Disease. Neurochem Int 2003,43:191-196

Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's Disease transgenic mice. J Neurochem 2003,85:1359-1367

Zhang L, Ulug AM, Zimmerman RD, Lin M, Rubin M, Beal MF. The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis. J Magn Reson Imaging 2003,17:521-527

Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in p0 cells. Exp Neurol 2003; 179:229-235

Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003, 207:71-76

Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's Disease. Ann Neurol 2003; 53:S39-S48

Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's Disease. Neuron 2003,37:899-909

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal M.F., Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosc Res 2003;74:278-285

Klivenyi P., Ferrante R.J., Gardian G., Browne S., Pierre-Etienne C, Beal M.F. Increased survival and neuroprotective effects of BN-82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003;86:267-272

Lorenzl S., De Pasquale G., Segal A.Z., Beal, M.F. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 2003;34,e37-e38

Klivenyi P., Gardian G., Calingasan N.Y., Yang L., Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's Disease. J Mol Neurosci 2003;21:191-198

Lin M. T. and Beal MF. The oxidative damage theory of aging. Clin Neurosci Res 2003; 2:305-315

Barberi T., Klivenyi P., Calingasan N.Y., Lee H., Kawamata H., Loonam K., Perrier A.L., Bruses J., Rubio M. E., Topf N., Tabar V., Harrison N. L., Beal M.F., Moore M. A., Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 2003; 21:1200-1207

Diano S., Matthews R.T., Patrylo P., Yang L., Beal M.F., Barnstable C.J., Horvath T.L.. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 2003;144:5014-5021

Andreassen OA., Ferrante RJ., Aamo TO., Beal MF., Jorgensen HA. Oral dyskinesias and histopathological alterations in susbstantia nigra after long-term haloperidol treatment of old rats. Neurosci 2003;122:717-725

Beal, M.F. Commentary - Alpha-synuclein and mitochondria: A tangled skein. Exp Neurol, in press

Beal M.F., Shults C.W. Effects of coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors 2003;18:153-161

Simon D.K., Lin M.T., Zheng L., Liu G.J., Ahn C.H., Kim L.M., Mauck W.M., Twu F., Beal M.F., Johns D.R. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's Disease. Neurobiol Aging 2004;25:71-81

Ulug A.M., Grunewald T., Lin M.T., Kamal A.K., Filippi C.G., Zimmerman R.D., Beal M.F. Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. J Magn Reson Imaging 2004;19:34-39

Browne S.E., Roberts II L.J., Dennery P.A., Doctrow S.R., Beal M.F. Barlow C., Levine R.L.. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Rad Biol Med 2004, 36:938-942

Klivenyi P., Kiaei M., Gardian G., Calingasan N.Y., Beal M.F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of ALS. J Neurochem 2004;88:576-582

Klivenyi P., Starkov A.A., Calingasan N.Y., Gardian G., Browne S.E., Yang L., Bubber P., Gibson G.E., Patel M.S., Beal M.F. Mice deficient in dihydrolipoamide dehydrogenase show incresed vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 2004, in press

Lorenzl S., Albers D.S., Chirichigno J.W., Augood S.J., Beal M.F. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. J Neurol Sci 2004; 218:39-45

Lorenzl S., Calingasan N., Yang L., Albers D.S., Shugama S., Gregorio J., Krell H. W., Chirichigno J., Joh T., Beal M.F. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuromolecular Med 2004, in press

Brownell A-L., Chen Y.I., Yu M., Wang X., Dedeoglu A., Beal M.F., Jenkins .G. 3-Nitroproionic acid induced neurotoxicity - assessed by ultra high resolution PET with comparison to MRI and MRS. J Neurochem 2004, in press

Klivenyi P., Calingasan N.Y., Stavrovskay I.G., Kristal B.S., Yang L., Petri S., Wieringa B., Beal M.F. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 2004, in press

Starkov A.A., Fiskum G., Chinopoulos C., Lorenzo B.J., Browne S.E. Patel M.S., Beal M.F Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Biol Cem 2004' submitted

Li F., Calingasan N.Y., Fangmin Y., Mauck W.M., Almeida C. G., Takahashi R. H., Carlson G. A., Beal M.F., Lin M.T., Gouras G.K. Increased beta-amyloid levels and plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 2004, in press

Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden  M, Borchelt D, Ross CA, Ferrante RF, Beal MF.  Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington’s Disease.  J Neurchem 2005;95:553-562

 

Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia.  FASEB J 2010,24: 4639-4647 PMID:  20667979

 

Banerjee R, Beal MF, Thomas B.  Autophagy in Neurodegeneration: Pathogenic roles and therapeutic implications.  Trends in Neurosciences 2010, 33:541-549

 

Choi DH, Hwang O, Lee KH, Lee J, Beal F, Kim YS.  DJ-1 clevage by matrix metalloproteinase 3 mediates oxidative stress induced dopaminergic cell death.  Antioxid Redox Signal 2010;14:2137-2150

 

Yao J, Hennessey T, Flynt A, Lai E, Beal M F, Lin MT.  MicroRNA-related cofilin abnormality in Alzheimer’s disease.  PLoS1 2010, 5:e15546

 

Dumont  M, Beal MF.  Neuroprotective strategies involving ROS in Alzheimer’s disease.  Free Rad Biol Med 2011;51:1014-1026.

 

Beal MF.  Neuroprotective effects of creatine.  Amino Acids 2011, 40:1305-1313

 

Zhang SF, Hennessey T, Starkova NN, Beal MF, Starkov AA.  Impaired brain creatine kinase activity in Huntington’s Disease. Neurodegenerative Dis  2010 doi:10.1159/000321681

 

Crawford CA, Akopian G, Ring J, Jakowec MW, Petzinger GM, Andersen JK, Vittozzi-Wong P, Wang K, Farley CM, Charntikov S, Mitroi D, Beal MF, Chow R, Walsh JP.  Acute and long-term response of dopamine nigrostriatal synapses to a single low dose episode of 3-nitroprionic acid-mediated chemical hypoxia.  Synapse 2011, 65:339-350 PMID: 20730800

 

Dumont M, Stack C, Elipenhali C, Calingasan NY, Wille E, Beal MF.  Apocynin administration doe not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer’s disease.  Neurosci Letts 2011, 492:150-154

 

Choi DH, Kim YJ, Kim YG, Joh TH, Beal MF, Kim YS.  The role of matrix metalloproteinase 3-mediated alpha-syuclein cleavage in dopaminergic cell death.  J Biol Chem 2011, 286:14168-14177. PMID:21330369

 

Neymotin A, Calingasan NY, Wille EJ, Naseri NN,  Petri S, Damiano M, Liby KT, Risingsong R, Sporn MB, Beal MF, Kiaei M.  Neuroprotective effect of Nrf2/ARE activators, CDDO- trifluoroethylamide in a mouse model of amyotrophic lateral sclerosis.  Free Rad Biol Med, 2011, 51:88-96  PMID: 21457778

 

Ramonet D, Daher JPL, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Tronscoso JC, McCaffery M, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ.  Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.  PLoS One 2011; 6:e18568. PMID 21494637.

 

Johri A, Chaturvedi RK, Beal MF.  Hugging tight in Huntington’s.  Nat Med 2011;17:514, PMID: 21457778

 

Thomas B, Banerjee R, Starkova N, Zhang S, Calingasan N, Yang L, Wille E, Lorenzo B, Ho D, Beal F, Starkov A.  Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP-mouse model of Parkinson’s disease.  Antioxid & Redox Signal 2012, 16:855-868 PMID: 21529244

 

Johri A, Starkov A, Hennessey T, Sharma A, Yang L, Beal MF.  Truncated peroxisome  proliferator activated receptor – Coactivator 1 (PGC1) splice variant is severely altered in Huntington’s Disease.  Neurodegen Dis 2011,8:496-503.PMID:21757867

 

Dumont D, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF. 

Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer’s disease.  J Alzheimer’s Dis 2011; 27:211-223.  PMID:21799249

 

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Yang L, Starkov A, Beal F.  Behavioral deficit, oxidative stress and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.  FASEB J 2011, 25:4063-4072 PMID 21825035

 

Neymotin, A., Calingasan, N.Y., Wille, E., Naseri, N., Petri, S., Damiano, M., Liby, K.T., Risingsong, R., Sporn, M., Beal, M.F., Kiaei, M. Neuroportective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.  Free Radic Biol Med 2011,51:88-96 PMID 21457778

 

Johri A., Calingasan NY, Hennessey TM, Sharma A, Yang L., Wille E, Chandra A, Beal MF.  Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease.  Hum Mol Genet, 2012, 21:1124-1137  PMID 22095692

 

Henchcliffe, C., Dodel R., Beal, M.F.  Biomarkers of Parkinson’s disease and dementia with Lewy bodies.  Prog Neurobiol 2011, 95:601-613. PMID: 21983334

 

Kriks, S., Shim, J-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carillo, L., Auyeung, G., Buch, A., Yang, L., Beal, M.F., Surmeier, J., Kordower, J.H., Tabar, V., Studer, L.  Derivatation of authentic midbrain dopamine neurons from human ESCs results in highly efficient engraftment in murine and primate models of PD.  Nature, 2011, 480:547-551. PMID: 22056989

 

Johri, A and Beal, MF. Antioxidants in Huntington’s disease.  Biochim Biophys Acta Molecular Basis of Disease 2012,1822: 664-674. PMID:22138129

 

Manji, H., Kato, T., Di Propsero, N.A., Ness, S., Beal, M.F., Krams, M., Chen, G.  Mitochondrially mediated plasticity in major psychiatric disorders.  Nat Rev Neurosci 2012, 13:293-307.  PMID: 22510887

 

Yao, J., Lin, M., Beal, M.F. Mitochondrial dysfunction in neurodegenerative diseases.  Neurodegenerative Diseases.  Nature Neurosci Rev 2012, in press

 

Choi DH, Cristovao AC, Guhathakurta S, Lee J, Toh TH, Beal MF, Kim YS. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson’s disease.  Antioxid Redox Signal  2012,16:1033-1045. PMID:22098189

 

Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahasi I, Cudkowicz ME.  Oral repreated-dose toxicity studies of coenzyme Q in beagle dogs.  Int J Toxicol 2012,31:58-69. PMID: 22267890

 

Islam R, Yang L, Sah M, Kannan K, Anamani D, Vijayan C, Kwok J, Cantino ME, Beal MF, Fridell YW.  A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson’s Disease model. Neurobiol Dis 2012, 46:137-146. PMID: 22266335

 

Elipenahli, C., Stack, C., Jainuddin, S., Gerges, M., Yang, L., Starkov, A., Beal, M.F., Dumont, M.  Behavioral improvement after chronic administration of Coenzyme Q10 in P301S transgenic mice.  J Alzheimers Dis 2012, 28:173-182, PMID:21971408

 

Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, Lees AJ, Betensky RA, Beal MF, Simon DK. Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy Body disease.  Ann Neurol 2012, 71:850-854. PMID 22718549

 

Gollamudi S, Johri A, Calingasan NY, Yang L, Elemento O, Beal MF. Concordant signaling

 pathways produced by pesticide exposure in mice correspond to human Parkinson’s

Disease pathways.  PLoS One, 2012; 7:e36191.  PMID: 22563483.

 

Johri A and Beal MF.  Muscling in on PGC-1alpha for improved quality of life in ALS.  Cell

Metabolism 2012, 15:567-569.  PMID: 22560208.

 

Chaturvedi RK, Hennessey T, Johri A, Tiwari S, Mishra D, Agarwal S, Kim YS, Beal MF.

Transducer of regulated CREB-binding proteins (TORCs) transcription and function is

 impaired in Huntington’s disease. Hum Mol Gen, 2012, 21:3474-3488.  PMID: 22589249

 

Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol

 Exp Ther, 2012, 342: 619-630 PMID: 22700435.

                 

Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR,

Yamamoto M, Kenslet TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B.

Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids

attenuate dopaminergic neurotoxicity in the MPTP-mouse model of Parkinson’s disease.

 Antioxid Redox Signal 2013; 18:139-157 PMID: 22746536.

 

Dumont M, Stack, C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingsan NY,

Yang L, Tampellini D, Starkov A, Chan RB, Pujol A, Beal MF.  Bezafibrate administration

improves behavioral deficits and tau pathology in P301S mice.  Human Mol Gen, 2012, 21:

5091-5105 PMID: 22922230.

 

Yao J, Ho D, Calingasan N, Pipalia NH, Lin M, Beal MF.  Neuroprotection by cyclodextrin

in cell and mouse models of Alzheimer’s disease. J Exp Med 2012, 209, 2501-2513 PMID:

23209315.

 

Chaturvedi R, Beal MF  Mitochondria targeted therapeutic approaches in Parkinson’s and

Huntington’s diseases.  Mol Cell Neurosci 2013, 55:101-114. PMID: 23220289

 

Elm JJ. NINDS NET-PD Investigators.  Design Innovations and baseline findings in a long-

term Parkinson’s trial:  the National Institute of Neurological Disorders and Stroke

Exploratory Trials in Parkinson’s Disease Long-Term Study-1.  Mov Disord. 2012, 27:

1513-1521. PMID: 23079770

 

Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal MF, Beck J, Flagg E,

Galpern WR, Harman J, Lang AE, Schwarzchild M, Tanner C, Shoulson I.  Dopamine

transporter imaging is associated with long-term outcomes in Parkinson’s disease.  Mov

Disord. 2012, 27: 1392-1397. PMID: 22976926

 

Franco MC, Ye Y, Refakis C, Feldman J, Stokes A, Basso M, Fernandez de Mera R,

Sparrow N, Calingasan N, Kiaei M, Rhoads T, Ma T, Grumet M, Barnes S, Beal MF,

Beckman J, Mehl R, Estevez A. Nitration of Hsp90 Induces Cell Death.  Proc Natl Acad Sci

 2013, 110:1102-1111. PMID: 23487751

 

Kiss G, Konrad C, Doczi J, Starkov A, Kawamata H, Manfredi G, Zhang S, Gibson G, Beal

MF, Adam-Vizi, V, Chinopoulos C. The negative impact of alpha-ketoglutarate

dehydrogenase complex deficiency on matrix substrate-level phosphorylation.  FASEB

2013, 27:2392-2406  PMID:23475850

 

Chaturvedi RK, Beal MF.  Mitochondrial diseases of the brain.  Free Radic Biol Med 2013,

63:1-29. PMID:23567191

 

Morato L, Galino J, Ruiz M, Calingasan NY,  Starkova A, Dumont M, Naudi A, Martinez JJ,

Aubourg P, Portero-Otin M, Pamplona R, Galea E, Beal MF, Ferrer I, Pujol A.  Pioglitazone

halts axonal degeneration in a mouse modle of X-linked adrenoleukodystrophy. Brain

2013, 136:2432-2443. PMID:23794606

 

Damiano M, Diguet E, Malgorn C, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D,

Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Deglon N, Beal MF, Brouillet

E. A role of mitochondrial complex II defects in genetic models of Huntington’s disease

 Expressing N-terminal fragments of mutant huntingtin.  Human Mol Gen 2013, 22:3869-

3882. PMID:23720495.

 

Inoue K, Rispoli J, Yang L, Macleod D, Beal MF, Klann E, Abeliovich A.  Coordinate

Regulation of Mature Dopaminergic Axon Morphology by Macroautophagy and the PTEN

Signaling Pathway. PLoS Genet 2013, 9:e1003845. PMID 24098148

 

Johri A, Chandra A, Beal MF.  PGC-1alpha, mitochondrial dysfunction and Huntington’s

disease.  Free Radic Biol Med 2013; 62:37-46. PMID:23602910.

 

The Parkinson Study Group SURE-PD Investigators. Schwartzchild MA, Ascherio A, Beal MF, Cuddkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal l, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T,  Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease:  A Randomized Clinical Trial.  JAMA Neurol 2014 71; (5) 543-52. PMID 24366103.

 

Weiduschat N, Mao X, Beal MF, Nirenberg M, Shungu D. Henchcliffe C. Sex differences

 in cerebal energy metabolism in Parkinson’s disease:  a phosphorus magnetic resonance

spectroscopic imaging study.  Parkinsonism Relat Disord. 2014. May;20 (5):545-8.

PMID 24593902

 

The Parkinson Study Group QE Investigators. Beal MF, Oakes D, Shoulson I, Henchcliffe

 C et al.  A randomized clinical trial of high dosage coenzyme Q10 in early Parkinson

 disease:  No evidence of benefit. JAMA Neurol. 2014 May;71(5):543-52. PMID:

 24664227

 

Chandra A, Johri A, Beal MF.  Prospects for neuroprotective therapies in prodromal Huntington’s disease.  Mov Disord 2014, 3:285-93. PMID: 24573776

 

Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jove M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 2014,  23: 3716-3732. PMID: 24556215.

 

Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M, Starkova N, Starkov AA, Calingasan NY, Tampellini D, Pujol A, Beal MF.  PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer’s disease.  FASEB J 2014, 28:1745-1755 PMID: 24398293.

 

Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C.  Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson’s Disease.  J. Neuroimaging 2013, 25: 105-110. PMID: 24325203

 

Boussicault L, Herard A-S, Caligasan N, Petit F, Malgorn C, Merienne N, Jan C, Gaillard

M-C, Cambon K, Lerchundi R, Barros LF, Escartin C, Delzescaux T, Mariani J, Gray, M,

Hantraye P, Beal, MF, Brouillet E, Vega C, Bonvento G.  Impaired brain energy

metabolism in Huntington Disease:  critical role of astrocyte-neuron interactions.  J. Cere

Blood Flow Metab.  2014, 34: 1500-1510.  PMID 24938402.

 

 

Shah M, Rajagopalan S,u L, Voshaar C, Shurubor Y, Beal F, Andersen JK, Gutta AK.  The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson’s disease.  J Neurochem 2014, 131: 74-85.  PMID: 24848702.

 

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Inestigators.  Measuring disease progression in early Parkinson disease:  the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.  JAMA Neurol. 2014, 71: 710-6.  PMID: 24711047.

 

Pujol A, Morato L, Ruiz M, Boada J, Calingasan N, Galino J, Guilera C, Jove M, Naudi A, Ferrer I, Pamplona R, Serrano M, Portero-Otin M, Beal F, Fourcade S.  Activation of Sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy. Cell Death Differ, 2015 in press.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Honors and Awards

1972

B. A. Cum Laude, Honors in Biology

1975

Alpha Omega Alpha, Medical Honorary Society, President Elect 1976

1976

Raven Society, Scholarship and Service Honorary Society of the University of Virginia

1982

NIH Young Investigator Award

1992

Derek Denny-Brown Neurological Scholar Award, American Neurologic Association

1993

Who’s Who in the East

1994

Who’s Who in the World

1994

Who’s Who in Science and Engineering

1995

American Neurologic Association Presidential Symposium Lecturer

1995

Honorary Masters Degree, Harvard University

1996

Andrew Mark Lippard Lecture, Columbia University

1997

Fred Plum Lecture, Cornell Unviersity

1998

American Society for Neurochemistry Plenary Lecture

1999

Temple Research Award, Alzheimer’s Association

1999

Grass Lectureship in Neuroscience

2000

Zenith Award, Alzheimer’s Disease Association

2000

ISI One Hundred Most Highly Cited Researchers in Neuroscience

2000

DANA Alliance for Brain Initiatives

2001

Honored Member, Strathmore’s Who’s Who

2001

America’s Top Doctors, Castle and Connolly

2001

Davey Lecture, Northwestern University

2001

Stephens Lecturer, University of Colorado

2001

Porcellati Lecture, European Society of Neurochemistry

2001

Castle Connolly, Top Doctors in the New York Metro Area

2001

Irwin Levy Lecturer, Washington University

2002

America’s Top Doctors, Castle and Connolly

2002

Castle Connolly, Top Doctors  in the New York Metro Area

2002

Who’s Who in Medicine and Healthcare

2002

Who’s Who Among America’s Teachers

2002

Who’s Who in America

2002

Who’s Who in the World

2002

Who’s Who of Professionals

2002

First Mirapex Award for Translational Research in Parkinson’s Disease

2002

Keynote Lecture, Berlin Neuroscience Forum

2003

Who’s Who in Medicine and  Healthcare

2003

Who’s Who in America

2003

Who’s Who in the World

2003

Castle Connolly, Top Doctors in the New York Metro Area

2003

America’s Top Physicians, Consumer Research Council of America

2003

Druker Lecturer, Beth Israel Hospital, Harvard University

2003

Institute of Medicine of the National Academy Sciences

2003

Utterback Lecture, University of Tennessee

2004

Who’s Who In America

2004

Who’s Who in Medicine and Healthcare

2004

America’s Top Doctors, Castle and Connolly

2004

Who’s Who in the World

2004

International Who’s Who of Professionals

2004

Fellow Member of the American Academy of Neurology

2005

Who’s Who in America

2005

Who’s Who in Science and Engineering

2005

First Vice President, American Neurological Association

2005

Fellow, New York Academy of Science

2005

Whos’ Who in The East

2006

Who’s Who in Medicine and Healthcare

2006

Who’s Who in the East

2006 - 2007

Who’s Who in Science and Engineering

2006

Who’s Who in America

2007 – 2008

Who’s Who in Science and Engineering

2008 – 2009

Who’s Who in Science and Engineering

2009-2010

Who’s Who in Medicine and Health Care

2009

2009

Guide to America’s Top Physicians

Madison Who’s Who

2009

Listed as one of the 50 most cited authors in Alzheimer’s Disease since 1995 by the ISI

2010

Marquis Who’s Who in America

2010

Who’s Who for Executive and Professionals

2009-2010

2000 Outstanding Scientists 2010

2010

Great Minds of the 21st Century

2011

Who’s Who in America

2011

Who’s Who in the East

2011

Who’s Who in Science and Engineering

2012

Strathmore’s Who’s Who for Executives and Professionals

2012

Who’s Who in America

2012

Who’s Who in Science and Engineering

2012

America’s Best Doctors

2013

Who’s Who in America

2013

America’s Best Doctors

2013Selected as one of the 400 most influential biomedical researchers based on total citations and h-index (Eur J Clin Inv 43, 1339-65, 2013)

2014

Who’s Who in The East

2014

Who’s Who in America

2014

America’s Best Doctors

2014

Honoris Causa Professor-Univrsity of Szeged

Szeged, Hungary

 

2014

Who’s Who in the East

 

2015

Who’s Who in America

 

2015

Who’s Who in Science and Engineering